Davita (DVA) Receiving Somewhat Critical Media Coverage, Analysis Shows
News articles about Davita (NYSE:DVA) have been trending somewhat negative this week, according to Alpha One. The research group, a service of Accern, identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Alpha One ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Davita earned a media sentiment score of -0.07 on Alpha One’s scale. Alpha One also assigned news coverage about the company an impact score of 68 out of 100, meaning that recent press coverage is likely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have effected AlphaOne Sentiment Analysis’s rankings:
- The Scout Investments Inc. Boosts Stake in Davita Inc (DVA) – BangaloreWeekly (bangaloreweekly.com)
- Paul Tudor Jones’ Top 4 Health Care Buys (finance.yahoo.com)
- DaVita Clinical Research Celebrates International Clinical Trials Day (finance.yahoo.com)
- Parametric Portfolio Associates LLC Has $23.331 Million Stake in Davita Inc (DVA) (xboxonezone.com)
- So This is Why DaVita Inc. (DVA) Is So Strong (hoyentv.com)
Several brokerages have recently weighed in on DVA. TheStreet raised Davita from a “c+” rating to a “b-” rating in a research report on Monday, April 3rd. Zacks Investment Research raised Davita from a “hold” rating to a “buy” rating and set a $77.00 target price for the company in a research report on Tuesday, April 18th. Finally, Royal Bank of Canada reissued a “hold” rating and issued a $62.00 price target on shares of Davita in a report on Friday, February 17th. Seven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Davita currently has a consensus rating of “Hold” and an average target price of $70.33.
Davita (NYSE:DVA) opened at 64.11 on Friday. Davita has a one year low of $54.50 and a one year high of $78.77. The company has a 50-day moving average price of $67.22 and a 200-day moving average price of $65.34. The company has a market capitalization of $12.48 billion, a price-to-earnings ratio of 10.53 and a beta of 1.02.
Davita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, May 2nd. The company reported $0.79 earnings per share for the quarter, missing the consensus estimate of $0.82 by $0.03. Davita had a return on equity of 16.16% and a net margin of 4.92%. The company had revenue of $3.70 billion during the quarter, compared to the consensus estimate of $3.69 billion. Equities research analysts anticipate that Davita will post $3.55 EPS for the current year.
In other Davita news, CEO Javier Rodriguez sold 1,294 shares of Davita stock in a transaction on Monday, May 15th. The shares were sold at an average price of $66.21, for a total transaction of $85,675.74. Following the completion of the sale, the chief executive officer now owns 99,111 shares of the company’s stock, valued at approximately $6,562,139.31. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William L. Roper sold 12,994 shares of Davita stock in a transaction on Thursday, May 4th. The stock was sold at an average price of $65.89, for a total transaction of $856,174.66. Following the sale, the director now directly owns 45,277 shares of the company’s stock, valued at approximately $2,983,301.53. The disclosure for this sale can be found here. Insiders have sold a total of 22,702 shares of company stock valued at $1,495,492 in the last ninety days. Company insiders own 2.10% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/05/19/davita-dva-receiving-somewhat-critical-media-coverage-analysis-shows.html.
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Stock Ratings for Davita Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita Inc and related stocks with our FREE daily email newsletter.